<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0186-4866</journal-id>
<journal-title><![CDATA[Medicina interna de México]]></journal-title>
<abbrev-journal-title><![CDATA[Med. interna Méx.]]></abbrev-journal-title>
<issn>0186-4866</issn>
<publisher>
<publisher-name><![CDATA[Edición y Farmacia S.A. de C.V.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0186-48662018000400019</article-id>
<article-id pub-id-type="doi">10.24245/mim.v34i4.1884</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Dosis atípica de bevacizumab en un paciente con síndrome de Osler-Weber-Rendu]]></article-title>
<article-title xml:lang="en"><![CDATA[Atypical dose of bevacizumab in a patient with Osler-Weber Rendu syndrome.]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Estrada-Martínez]]></surname>
<given-names><![CDATA[Luis Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Rodríguez]]></surname>
<given-names><![CDATA[William Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Ortega]]></surname>
<given-names><![CDATA[Gabriela Noemí]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Iturbide-Escamilla]]></surname>
<given-names><![CDATA[Alberto Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chapuli-Azcatl]]></surname>
<given-names><![CDATA[Francisco Javier]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,ISSSTE  ]]></institution>
<addr-line><![CDATA[ Puebla]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,ISSSTE  ]]></institution>
<addr-line><![CDATA[ Puebla]]></addr-line>
</aff>
<aff id="Af3">
<institution><![CDATA[,ISSSTE  ]]></institution>
<addr-line><![CDATA[ Puebla]]></addr-line>
</aff>
<aff id="Af4">
<institution><![CDATA[,ISSSTE  ]]></institution>
<addr-line><![CDATA[ Puebla]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2018</year>
</pub-date>
<volume>34</volume>
<numero>4</numero>
<fpage>649</fpage>
<lpage>657</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0186-48662018000400019&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0186-48662018000400019&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0186-48662018000400019&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El síndrome de Osler-Weber-Rendu es una enfermedad de transmisión autosómica dominante. Si bien el síntoma más común es la epistaxis, existen muchas alteraciones viscerales que deben considerarse al momento del estudio. Los anti-VEFG son un pilar en el tratamiento, aunque no existe consenso acerca de la dosis a administrar. Comunicamos el caso de un paciente con síndrome de Osler-Weber-Rendu atendido en el servicio de Medicina Interna del Hospital Regional de Puebla, al que se prescribió una dosis atípica de bevacizumab con buena respuesta terapéutica.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Osler-Weber-Rendu syndrome is an autosomical dominant condition. Although epistaxis is the most frequent symptom, many other visceral implications have to be considered while the workup takes place. While Anti-VEGF are the cornerstone of the treatment, there is no consensus regarding the specific dose to be administered. We communicate de case of a patient with Osler-Weber-Rendu syndrome attended at our Hospital in which we prescribed an atypical dose of bevacizumab with good outcome.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Síndrome de Osler-Weber-Rendu]]></kwd>
<kwd lng="es"><![CDATA[bevacizumab]]></kwd>
<kwd lng="es"><![CDATA[telangiectasia]]></kwd>
<kwd lng="es"><![CDATA[epistaxis]]></kwd>
<kwd lng="en"><![CDATA[Osler-Weber-Rendu Syndrome]]></kwd>
<kwd lng="en"><![CDATA[Bevacizumab]]></kwd>
<kwd lng="en"><![CDATA[Telangiectasis]]></kwd>
<kwd lng="en"><![CDATA[Epistaxis]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Ross]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Berard]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Figueroa-Bodine]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Livada]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Richer]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Very low dose bevacizumab for the treatment of pistaxis in patients with hereditary hemorrhagic telangiectasia]]></article-title>
<source><![CDATA[Allergy Rhinol]]></source>
<year>2014</year>
<volume>5</volume>
<page-range>e91-5</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parambil]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hereditary hemorrhagic telangiectasia]]></article-title>
<source><![CDATA[Clin Chest Med]]></source>
<year>2016</year>
<volume>37</volume>
<page-range>513-21</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Epperla]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Hocking]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Blessing for the bleeder Bevacizumab in hereditary hemorrhagic telangiectasia]]></article-title>
<source><![CDATA[Clin Med Res]]></source>
<year>2015</year>
<volume>13</volume>
<page-range>32-5</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stellar]]></surname>
<given-names><![CDATA[LI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heredetary Telangiectasis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1942</year>
<volume>226</volume>
<page-range>336-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dupuis-Girod]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ginon]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Saurin]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Marion]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Guillot]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Decullier]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2012</year>
<volume>307</volume>
<page-range>948-55</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Combariza]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Oyala]]></surname>
<given-names><![CDATA[VP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hereditary hemorrhagic telangiectasia Osler Weber Rendu syndrome and management with bevacizumab]]></article-title>
<source><![CDATA[Acta Med Colomb]]></source>
<year>2015</year>
<volume>40</volume>
<page-range>66-8</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fertoli]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Lallone]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Barton]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravenous bevacizumab therapy in a patient with hereditary hemorrhagic telangiectasia, ENG E137K, alcoholic cirrhosis, and portal hypertension]]></article-title>
<source><![CDATA[Case Rep Gastroenterol]]></source>
<year>2017</year>
<volume>11</volume>
<page-range>293-304</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lacombe]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lacout]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Marcy]]></surname>
<given-names><![CDATA[PY]]></given-names>
</name>
<name>
<surname><![CDATA[Binsse]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and treatment of pulmonary arteriovenous malformations in hereditary hemorrhagic telangiectasia an overview. Diagnostic and Invertentional]]></article-title>
<source><![CDATA[Imaging]]></source>
<year>2013</year>
<volume>94</volume>
<page-range>835-48</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brinjikji]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Iyer]]></surname>
<given-names><![CDATA[VN]]></given-names>
</name>
<name>
<surname><![CDATA[Sorenson]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lanzino]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cerebrovascular manifestations of hereditary hemorrhagic telangiectasia]]></article-title>
<source><![CDATA[Stroke]]></source>
<year>2015</year>
<volume>46</volume>
<page-range>3329-37</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bernabéu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Blanco]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Langa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Garrido-Martin]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Botella]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Involvement of the TGF-ß superfamily signalling pathway inhereditary haemorrhagic telangiectasia]]></article-title>
<source><![CDATA[J Appl Biomed]]></source>
<year>2010</year>
<volume>8</volume>
<page-range>169-77</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McKusick]]></surname>
<given-names><![CDATA[VA.]]></given-names>
</name>
<name>
<surname><![CDATA[Osler]]></surname>
</name>
<name>
<surname><![CDATA[Weber]]></surname>
<given-names><![CDATA[HHT]]></given-names>
</name>
</person-group>
<source><![CDATA[Telangiectasia, hereditary hemorrhagic, of Rendu]]></source>
<year>1986</year>
<publisher-name><![CDATA[OMIM]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McDonald]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wooderchak-Donahue]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[VanSant Webb]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Whitehead]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Stevenson]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Bayrak-Toydemir]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hereditary hemorrhagic telangiectasia genetics and molecular diagnostics in a new era]]></article-title>
<source><![CDATA[Front Genet]]></source>
<year>2015</year>
<volume>6</volume>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schelker]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Barreiros]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Hart]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Herr]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Macro- and microcirculation patterns of intrahepatic blood flow changes in patients with hereditary hemorrhagic telangiectasia]]></article-title>
<source><![CDATA[World J Gastroenterol]]></source>
<year>2017</year>
<volume>23</volume>
<page-range>486-95</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Faughnan]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Palda]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia-Tsao]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Geisthoff]]></surname>
<given-names><![CDATA[UW]]></given-names>
</name>
<name>
<surname><![CDATA[McDonald]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Proctor]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia]]></article-title>
<source><![CDATA[J Med Genet]]></source>
<year>2011</year>
<volume>48</volume>
<page-range>73-87</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Geisthoff]]></surname>
<given-names><![CDATA[UW]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
<name>
<surname><![CDATA[Röth]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Seyfert]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[How to manage patients with hereditary haemorrhagic telangiectasia]]></article-title>
<source><![CDATA[Br J Haematol]]></source>
<year>2015</year>
<volume>171</volume>
<page-range>443-52</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garg]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Khunger]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimal management of hereditary hemorrhagic telangiectasia]]></article-title>
<source><![CDATA[J Blood Med]]></source>
<year>2014</year>
<volume>5</volume>
<page-range>191-206</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Circo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gossage]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pulmonary vascular complications of hereditary haemorrhagic telangiectasia]]></article-title>
<source><![CDATA[Curr Opin Pulm Med]]></source>
<year>2014</year>
<volume>20</volume>
<page-range>421-8</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krynytska]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Marushchak]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mikolenko]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bob]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Smachylo]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Radetska]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Differential diagnosis of hepatopulmonary syndrome (HPS): Portopulmonary hypertension (PPH) and hereditary hemorrhagic telangiectasia (HHT)]]></article-title>
<source><![CDATA[Bosn J Basic Med Sci]]></source>
<year>2017</year>
<volume>17</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>276-85</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Swanon]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Hathcock]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Kremers]]></surname>
<given-names><![CDATA[WK]]></given-names>
</name>
<name>
<surname><![CDATA[Pallanch]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Krowka]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identifying the presence of clinically significant hepatic involvement in hereditary haemorrhagic telangiectasia using a simple clinical scoring index]]></article-title>
<source><![CDATA[J Hepatol]]></source>
<year>2014</year>
<volume>61</volume>
<page-range>124-31</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kanellopoulou]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Alexopoulou]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia]]></article-title>
<source><![CDATA[Expert Opin Biol Ther]]></source>
<year>2013</year>
<volume>13</volume>
<page-range>1315-26</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zarrabeitia]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Albiñana]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Salcedo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Señaris-Gonzalez]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Fernandez-Forcelledo]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Botella]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A review on clinical management and pharmacological therapy on hereditary haemorrhagic telangiectasia (HHT)]]></article-title>
<source><![CDATA[Curr Vasc Pharmacol]]></source>
<year>2010</year>
<volume>8</volume>
<page-range>473-81</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ou]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Galoport]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Enns]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bevacizumab and gastrointestinal bleeding in hereditary hemorrhagic telangiectasia]]></article-title>
<source><![CDATA[World J Gastrointest Surg]]></source>
<year>2016</year>
<volume>8</volume>
<page-range>792-5</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Azzopardi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Dupuis-Girod]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ternant]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Fargeton]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Ginon]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Faure]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia]]></article-title>
<source><![CDATA[MAbs]]></source>
<year>2015</year>
<volume>7</volume>
<page-range>630-7</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
